Jillion Therapeutics Inc.

Jillion Therapeutics is an early-stage biotechnology company developing novel small-molecule therapeutics for central nervous system (CNS) disorders. Our mission is to address critical unmet medical needs through a focused, mechanism-driven approach to drug discovery. By targeting pathways often overlooked in traditional CNS drug development, we aim to deliver transformative treatments for conditions with limited or no effective therapies. Nobel-Inspired Drug Development: Pioneering CNS Therapies of Tomorrow, with a specific emphasis on Substance Use Disorders (SUDs) and Neurodegeneration. With over two decades of experience in a Nobel Prize-winning lab, Jillion's Scientific founder brings unparalleled expertise in brain signaling and disease mechanisms, combined to state-of-the-art molecular approaches. Creativity meets Innovation to disrupt the drug discovery process: Jillion’s efforts are accelerating pre-clinical drug discovery by rapidly generating a wide array of new drug leads for innovative CNS treatments, with potential relevance for oncology and metabolic diseases. Seamless Integration of Chemistry, Neuroscience, HPS Drug Screening and A.I./M.L.: Proprietary and licensed methods tightly couple chemistry with neuroscience and High-Power Screening (HPS), while A.I. and machine learning will drive hit and lead optimization.